Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199718 | 0.98 | KDM4E (0.31) | KDM4EMAPTMEN1LMNAOPRK1 | |
| SCHEMBL19636193 | 0.94 | SIRT2 (0.33) | KDM4EMAPTMEN1LMNAOPRK1 | |
| SCHEMBL20199647 | 0.93 | SIRT2 (0.33) | KDM4EMAPTMEN1LMNAOPRK1 | |
| SCHEMBL20199608 | 0.91 | KDM4E (0.32) | KDM4EMAPTATML3MBTL1SIRT2 | |
| SCHEMBL20199723 | 0.91 | PDE6D (0.30) | — | |
| SCHEMBL20203660 | 0.91 | LMNA (0.30) | KDM4EMAPTMEN1LMNAOPRK1 | |
| SCHEMBL20199738 | 0.90 | KDM4E (0.38) | KDM4EATML3MBTL1 | |
| SCHEMBL20199741 | 0.90 | KDM4E (0.35) | KDM4EATML3MBTL1 | |
| SCHEMBL20199736 | 0.89 | KDM4E (0.37) | KDM4EATML3MBTL1 | |
| SCHEMBL20199724 | 0.89 | PDE10A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | LG CHEM, LTD. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | DCX, TERT, TELO2 | KDM4E 1392/4885MAPT 1276/4885MEN1 2052/4885 |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | DCX, TERT, TELO2 | KDM4E 1392/4885MAPT 1276/4885MEN1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.